MRC Laboratory of Molecular Biology

One of the world's leading research institutes, our scientists are working to advance understanding of biological processes at the molecular level - providing the knowledge needed to solve key problems in human health.

Home > LMB In The News > SELPEPCON – an exciting technology platform developed by the LMB’s Mike Gait

SELPEPCON – an exciting technology platform developed by the LMB’s Mike Gait

Published on

A technology platform to deliver cargoes using arrays of cell penetrating peptides was developed by the LMB’s Mike Gait, to help treat muscular degenerative diseases such as Duchenne muscular dystrophy. Further developments on this SELPEPCON technology, which was patented by the MRC and is licenced to Cambridge Research Biochemicals, are highlighted here.